Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 6/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311516 | 0.86 | PDE8B (0.40) | GRM5HCRTR2 | |
| SCHEMBL311133 | 0.81 | HCRTR1 (0.54) | HCRTR2 | |
| SCHEMBL4167405 | 0.80 | ALDH1A1 (0.38) | TDP1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3251052 | 0.76 | PDE8B (0.38) | TDP1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4167672 | 0.76 | RHOC (0.38) | DAGLAABHD6 | |
| SCHEMBL4167801 | 0.74 | DAGLA (0.38) | DAGLAABHD6 | |
| SCHEMBL4159081 | 0.72 | KDM4E (0.42) | TDP1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3470606 | 0.71 | ALDH1A1 (0.39) | NPC1RAB9AKMT2AMEN1DAGLA | |
| SCHEMBL4163254 | 0.69 | DPP4 (0.39) | NPC1RAB9AKMT2AMEN1DAGLA | |
| SCHEMBL3472074 | 0.69 | SMN1; SMN2 (0.38) | NPC1RAB9AKMT2AMEN1DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160344-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160344-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ENTPD5 | TDP1 2077/4885NPC1 255/4885RAB9A 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.